FDA Finalizing Opioid REMS Proposal, Sets Joint Advisory Committee Meeting For July
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants to gather feedback from advisors and from the public on the classwide REMS for opioid analgesics, and judging from the stakeholder meetings the agency has held so far, it will get an earful.